AstraZeneca Gets Approval for Forxiga to Treat Chronic Kidney Diseases in Japan

The pharmaceutical company ‘AstraZeneca’ has recently announced that, Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 inhibitor (SGLT2), has been now approved in the country of Japan for the treatment of the chronic kidney disease (CKD) in the adult people suffering with or without type-2 diabetes (T2D). The approval from the ministry of health, labour and welfare […]

Continue Reading